Expertise in
4
conditions

Massimo Di Nicola

Milan, IT 
Expertise in
4
conditions
Milan, IT 

Overview

Massimo Di Nicola practices practicing medicine in Milan, Italy.

Mr. Di Nicola is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Triple-Negative Breast Cancer, Gamma Knife Radiosurgery, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 57 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

Milan, Italy
Other Locations
Bolzano, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

An International Phase II Trial Assessing Tolerability and Efficacy of Sequential Methotrexate-Aracytin-based Combination and R-ICE Combination, Followed by HD Chemotherapy Supported by ASCT, in Patients With Systemic B-cell Lymphoma With CNS Involvement at Diagnosis or Relapse (MARIETTA Regimen)
An International Phase II Trial Assessing Tolerability and Efficacy of Sequential Methotrexate-Aracytin-based Combination and R-ICE Combination, Followed by HD Chemotherapy Supported by ASCT, in Patients With Systemic B-cell Lymphoma With CNS Involvement at Diagnosis or Relapse (MARIETTA Regimen)
Enrollment Status: Completed
Publish Date: July 08, 2025
Intervention Type: Drug, Radiation
Study Drugs: Methotrexate, Rituximab, Cytarabine, Thiotepa, Liposomal Cytarabine, Etoposide, Ifosfamide, Carmustine
Study Phase: Phase 2
A Phase Ib Open-Label, Dose-Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid Tumors
A Phase Ib Open-Label, Dose-Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: September 20, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug
Study Phase: Phase 1
Phase II Study on Safety and Activity of a Short Term Intensified Chemo-immunotherapy Combination in HIV-positive Patients Affected by Burkitt Lymphoma
Phase II Study on Safety and Activity of a Short Term Intensified Chemo-immunotherapy Combination in HIV-positive Patients Affected by Burkitt Lymphoma
Enrollment Status: Completed
Publish Date: August 04, 2022
Intervention Type: Drug, Radiation
Study Drugs: Intensive Short Term Immuno-Chemotherapy, Cytarabine+Rituximab+Leukapheresis, BEAM Conditioning
Study Phase: Phase 2
Use of TPO-mimetics to Prepare for Splenectomy in Adult Patients With Primary Immune Thrombocytopenia. Brooklyn Observational Retrospective Study.
Use of TPO-mimetics to Prepare for Splenectomy in Adult Patients With Primary Immune Thrombocytopenia. Brooklyn Observational Retrospective Study.
Enrollment Status: Completed
Publish Date: October 14, 2020
View 4 Less Clinical Trials

57 Total Publications

CAR-engineering of innate and innate-like immune cells: a new horizon in adoptive cell therapy for solid tumors.
CAR-engineering of innate and innate-like immune cells: a new horizon in adoptive cell therapy for solid tumors.
Journal: Journal for immunotherapy of cancer
Published: April 18, 2026

Frequently Asked Questions about Massimo Di Nicola

Is Massimo Di Nicola a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Massimo Di Nicola is classified as an Advanced expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Massimo Di Nicola participate in research or clinical trials?

Yes. Massimo Di Nicola has published 57 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Massimo Di Nicola's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Di Nicola's expertise for a condition
ConditionClose
      View All 18 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile